The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
The emerging spectrum of COVID-19 neurology: clinical, radiological and laboratory findings
Open accessAbstract
Preliminary clinical data indicate that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is associated with neurological and neuropsychiatric illness. Responding to this, a weekly virtual coronavirus disease 19 (COVID-19) neurology multi-disciplinary meeting was established at the National Hospital, Queen Square, in early March 2020 in order to discuss and begin to understand neurological presentations in patients with suspected COVID-19-related neurological disorders. Detailed clinical and paraclinical data were collected from cases where the diagnosis of COVID-19 was confirmed through RNA PCR, or where the diagnosis was probable/possible according to World Health Organization criteria. Of 43 patients, 29 were SARS-CoV-2 PCR positive and definite, eight probable and six possible. Five major categories emerged: (i) encephalopathies (n = 10) with delirium/psychosis and no distinct MRI or CSF abnormalities, and with 9/10 making a full or partial recovery with supportive care only; (ii) inflammatory CNS syndromes (n = 12) including encephalitis (n = 2, para- or post-infectious), acute disseminated encephalomyelitis (n = 9), with haemorrhage in five, necrosis in one, and myelitis in two, and isolated myelitis (n = 1). Of these, 10 were treated with corticosteroids, and three of these patients also received intravenous immunoglobulin; one made a full recovery, 10 of 12 made a partial recovery, and one patient died; (iii) ischaemic strokes (n = 8) associated with a pro-thrombotic state (four with pulmonary thromboembolism), one of whom died; (iv) peripheral neurological disorders (n = 8), seven with Guillain-Barré syndrome, one with brachial plexopathy, six of eight making a partial and ongoing recovery; and (v) five patients with miscellaneous central disorders who did not fit these categories. SARS-CoV-2 infection is associated with a wide spectrum of neurological syndromes affecting the whole neuraxis, including the cerebral vasculature and, in some cases, responding to immunotherapies. The high incidence of acute disseminated encephalomyelitis, particularly with haemorrhagic change, is striking. This complication was not related to the severity of the respiratory COVID-19 disease. Early recognition, investigation and management of COVID-19-related neurological disease is challenging. Further clinical, neuroradiological, biomarker and neuropathological studies are essential to determine the underlying pathobiological mechanisms that will guide treatment. Longitudinal follow-up studies will be necessary to ascertain the long-term neurological and neuropsychological consequences of this pandemic.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884
Clinical characteristics of coronavirus disease 2019 in China
Guan, W.-J., Ni, Z.-Y., Hu, Y., Liang, W.-H., Ou, C.-Q., He, J.-X., Liu, L., Shan, H., Lei, C.-L., Hui, D. S. C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2002032 · Cited by 30,246
Chen, N., Zhou, M., Dong, X., Qu, J., Gong, F., Han, Y., Qiu, Y., Wang, J., Liu, Y., Wei, Y., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30211-7 · Cited by 21,415
Wu, Z., & McGoogan, J. M. (2020) · JAMA · doi:10.1001/jama.2020.2648 · Cited by 17,016
COVID-19: consider cytokine storm syndromes and immunosuppression
Mehta, P., McAuley, D. F., Brown, M., Sanchez, E., Tattersall, R. S., & Manson, J. J. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30628-0 · Cited by 9,664
Self-citationNeurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China
Mao, L., Jin, H., Wang, M., Hu, Y., Chen, S., He, Q., Chang, J., Hong, C., Zhou, Y., Wang, D., et al. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2020.1127 · Cited by 7,166 · cited 2×
“Discussion The widespread effects of COVID-19 include neurological disorders but there have been, to date, no detailed clinical reports of their nature (Guan et al., 2020; Helms et al., 2020; Mao et al., 2020; Varatharaj et al., 2020).”
BackgroundEndothelial cell infection and endotheliitis in COVID-19
Varga, Z., Flammer, A. J., Steiger, P., Haberecker, M., Andermatt, R., Zinkernagel, A. S., Mehra, M. R., Schuepbach, R. A., Ruschitzka, F., & Moch, H. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30937-5 · Cited by 6,358
Tang, N., Li, D., Wang, X., & Sun, Z. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14768 · Cited by 5,662
A clinical approach to diagnosis of autoimmune encephalitis
Graus, F., Titulaer, M. J., Balu, R., Benseler, S., Bien, C. G., Cellucci, T., Cortese, I., Dale, R. C., Gelfand, J. M., Geschwind, M., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00401-9 · Cited by 4,516
Self-citationNeurologic features in severe SARS-CoV-2 infection
Helms, J., Kremer, S., Merdji, H., Clere-Jehl, R., Schenck, M., Kummerlen, C., Collange, O., Boulay, C., Fafi-Kremer, S., Ohana, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmc2008597 · Cited by 2,674
Cited by
Nalbandian, A., Sehgal, K., Gupta, A., Madhavan, M. V., McGroder, C., Stevens, J. S., Cook, J. R., Nordvig, A. S., Shalev, D., Sehrawat, T. S., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01283-z · Cited by 4,862
Taquet, M., Geddes, J. R., Husain, M., Luciano, S., & Harrison, P. J. (2021) · The Lancet Psychiatry · doi:10.1016/s2215-0366(21)00084-5 · Cited by 2,189
SARS-CoV-2 is associated with changes in brain structure in UK Biobank
Douaud, G., Lee, S., Alfaro-Almagro, F., Arthofer, C., Wang, C., McCarthy, P., Lange, F., Andersson, J. L. R., Griffanti, L., Duff, E., et al. (2022) · Nature · doi:10.1038/s41586-022-04569-5 · Cited by 1,646
Long COVID or post-COVID-19 syndrome: putative pathophysiology, risk factors, and treatments
Yong, S. J. (2021) · Infectious Diseases · doi:10.1080/23744235.2021.1924397 · Cited by 1,339
“Another study documenting 43 cases of COVID-19-induced serious brain diseases (e.g. encephalopathies, delirium, haemorrhage, and stroke) also found that initial COVID-19 severity plays little role in predicting these brain diseases [68].”
BackgroundHow and why patients made Long Covid
Callard, F., & Perego, E. (2021) · Social Science & Medicine · doi:10.1016/j.socscimed.2020.113426 · Cited by 924
Cognitive deficits in people who have recovered from COVID-19
Hampshire, A., Trender, W., Chamberlain, S. R., Jolly, A. E., Grant, J. E., Patrick, F., Mazibuko, N., Williams, S. C., Barnby, J. M., Hellyer, P., et al. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.101044 · Cited by 701
Frequent neurologic manifestations and encephalopathy‐associated morbidity in Covid‐19 patients
Liotta, E. M., Batra, A., Clark, J. R., Shlobin, N. A., Hoffman, S. C., Orban, Z. S., & Koralnik, I. J. (2020) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51210 · Cited by 526
Lifting the mask on neurological manifestations of COVID-19
Pezzini, A., & Padovani, A. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-0398-3 · Cited by 447
Abu-Rumeileh, S., Abdelhak, A., Foschi, M., Tumani, H., & Otto, M. (2021) · Journal of Neurology · doi:10.1007/s00415-020-10124-x · Cited by 419
Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection
Patone, M., Handunnetthi, L., Saatci, D., Pan, J., Katikireddi, S. V., Razvi, S., Hunt, D., Mei, X. W., Dixon, S., Zaccardi, F., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01556-7 · Cited by 394
COVID-19: from an acute to chronic disease? Potential long-term health consequences
Higgins, V., Sohaei, D., Diamandis, E. P., & Prassas, I. (2021) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2020.1860895 · Cited by 405
LaRovere, K. L., Riggs, B. J., Poussaint, T. Y., Young, C. C., Newhams, M. M., Maamari, M., Walker, T. C., Singh, A. R., Dapul, H., Hobbs, C. V., et al. (2021) · JAMA Neurology · doi:10.1001/jamaneurol.2021.0504 · Cited by 396
Cognitive impairment and altered cerebral glucose metabolism in the subacute stage of COVID-19
Hosp, J. A., Dressing, A., Blazhenets, G., Bormann, T., Rau, A., Schwabenland, M., Thurow, J., Wagner, D., Waller, C., Niesen, W. D., et al. (2021) · Brain · doi:10.1093/brain/awab009 · Cited by 384
Epidemiological and cohort study finds no association between COVID-19 and Guillain-Barré syndrome
Keddie, S., Pakpoor, J., Mousele, C., Pipis, M., Machado, P. M., Foster, M., Record, C. J., Keh, R. Y. S., Fehmi, J., Paterson, R. W., et al. (2021) · Brain · doi:10.1093/brain/awaa433 · Cited by 333
Self-citationSystemic and organ-specific immune-related manifestations of COVID-19
Ramos-Casals, M., Brito-Zerón, P., & Mariette, X. (2021) · Nature Reviews Rheumatology · doi:10.1038/s41584-021-00608-z · Cited by 309
A Prospective Study of Neurologic Disorders in Hospitalized Patients With COVID-19 in New York City
Frontera, J. A., Sabadia, S., Lalchan, R., Fang, T., Flusty, B., Millar-Vernetti, P., Snyder, T., Berger, S., Yang, D., Granger, A., et al. (2021) · Neurology · doi:10.1212/wnl.0000000000010979 · Cited by 291
Fodoulian, L., Tuberosa, J., Rossier, D., Boillat, M., Kan, C., Pauli, V., Egervari, K., Lobrinus, J. A., Landis, B. N., Carleton, A., et al. (2020) · doi:10.1101/2020.03.31.013268 · Cited by 286
High frequency of cerebrospinal fluid autoantibodies in COVID-19 patients with neurological symptoms
Franke, C., Ferse, C., Kreye, J., Reincke, S. M., Sanchez-Sendin, E., Rocco, A., Steinbrenner, M., Angermair, S., Treskatsch, S., Zickler, D., et al. (2021) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2020.12.022 · Cited by 275
Neurological and cognitive sequelae of COVID-19: a four month follow-up.
Mattioli, F., Stampatori, C., Righetti, F., Sala, E., Tomasi, C., & De Palma, G. (2021) · Journal of Neurology · doi:10.1007/s00415-021-10579-6 · Cited by 160
Neuropathobiology of COVID-19: The Role for Glia
Tremblay, M.-E., Madore, C., Bordeleau, M., Tian, L., & Verkhratsky, A. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.592214 · Cited by 159
“Similarly, the clinical presentation of COVID-19 frequently includes neurological symptoms and neuropathologies such as acute ischemic stroke, meningitis/encephalitis, acute necrotising haemorrhagic encephalopathy, acute Guillain–Barré syndrome (Beyrouti et al., 2020; Dixon et al., 2020; Oxley et al., 2020; Paterson e…”
BackgroundInfectious agents and Alzheimer's disease
Piekut, T., Hurła, M., Banaszek, N., Szejn, P., Dorszewska, J., Kozubski, W., & Prendecki, M. (2022) · Journal of Integrative Neuroscience · doi:10.31083/j.jin2102073 · Cited by 123
Li, X., Raventós, B., Roel, E., Pistillo, A., Martinez-Hernandez, E., Delmestri, A., Reyes, C., Strauss, V., Prieto-Alhambra, D., Burn, E., et al. (2022) · BMJ · doi:10.1136/bmj-2021-068373 · Cited by 118
A genetic link between risk for Alzheimer's disease and severe COVID-19 outcomes via the OAS1 gene
Magusali, N., Graham, A. C., Piers, T. M., Panichnantakul, P., Yaman, U., Shoai, M., Reynolds, R. H., Botia, J. A., Brookes, K. J., Guetta-Baranes, T., et al. (2021) · Brain · doi:10.1093/brain/awab337 · Cited by 111
“Coupling these findings with the high incidence of neurological problems in people showing a severe COVID-19 response, 37– 40 emphasizes the urgency with which we need to understand the mechanisms underlying the changes to cytokine signalling regulated by interferon signalling, particularly to…”
BackgroundAlquisiras-Burgos, I., Peralta-Arrieta, I., Alonso-Palomares, L. A., Zacapala-Gómez, A. E., Salmerón-Bárcenas, E. G., & Aguilera, P. (2021) · Molecular Neurobiology · doi:10.1007/s12035-020-02134-7 · Cited by 115
COVID-19 and psychosis risk: real or delusional concern?
Watson, C. J., Thomas, R. H., Solomon, T., Michael, B. D., Nicholson, T. R., & Pollak, T. A. (2021) · Neuroscience Letters · doi:10.1016/j.neulet.2020.135491 · Cited by 103
Klaser, K., Thompson, E. J., Nguyen, L. H., Sudre, C. H., Antonelli, M., Murray, B., Canas, L. S., Molteni, E., Graham, M. S., Kerfoot, E., et al. (2021) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2021-327565 · Cited by 84
Clough, E., Inigo, J., Chandra, D., Chaves, L., Reynolds, J. L., Aalinkeel, R., Schwartz, S. A., Khmaladze, A., & Mahajan, S. D. (2021) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-021-10015-6 · Cited by 75
“The clinical presentation of COVID-19 is associated with significant neurological symptoms and neuropathologies such as acute ischemic stroke, meningitis/encephalitis, anosmia, neuromuscular diseases, epileptic seizures, focal neurological deficits as well as neuropsychological abnormalities such as depression, deliri…”
BackgroundSerrano del Pueblo, V. M., Serrano-Heras, G., Romero Sánchez, C. M., Landete, P. P., Rojas-Bartolome, L., Feria, I., Morris, R. G. M., Strange, B., Mansilla, F., Zhang, L., et al. (2024) · Brain · doi:10.1093/brain/awae101 · Cited by 71
Acute disseminated encephalomyelitis (ADEM) following recent Oxford/AstraZeneca COVID-19 vaccination
Permezel, F., Borojevic, B., Lau, S., & de Boer, H. H. (2022) · Forensic Science, Medicine and Pathology · doi:10.1007/s12024-021-00440-7 · Cited by 62
Amyloid processing in COVID‐19‐associated neurological syndromes
Ziff, O. J., Ashton, N. J., Mehta, P. R., Brown, R., Athauda, D., Heaney, J., Heslegrave, A. J., Benedet, A. L., Blennow, K., Checkley, A. M., et al. (2022) · Journal of Neurochemistry · doi:10.1111/jnc.15585 · Cited by 54
Self-citationVitaliano, G. D., Kim, J. K., Kaufman, M. J., Adam, C. W., Zeballos, G., Shanmugavadivu, A., Subburaju, S., McLaughlin, J. P., Lukas, S. E., & Vitaliano, F. (2022) · Communications Biology · doi:10.1038/s42003-022-03177-3 · Cited by 48
Rabinovitz, B., Jaywant, A., & Fridman, C. B. (2020) · The Clinical Neuropsychologist · doi:10.1080/13854046.2020.1803408 · Cited by 46
Davé, V. A., & Klein, R. S. (2023) · Glia · doi:10.1002/glia.24294 · Cited by 29
“While there is little evidence of SARS-CoV-2 neuroinvasion (Espíndola et al., 2021; Paterson et al., 2020; Thakur et al., 2021), clinical studies report blood–brain bar- rier (BBB) disruption, and microglial activation in various brain regions upon post-mortem examination.”
BackgroundPost-COVID-19 Parkinsonism and Parkinson’s Disease Pathogenesis: The Exosomal Cargo Hypothesis
Mysiris, D. S., Vavougios, G. D., Karamichali, E., Papoutsopoulou, S., Stavrou, V. T., Papayianni, E., Boutlas, S., Mavridis, T., Foka, P., Zarogiannis, S. G., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23179739 · Cited by 25
Metadata
- Authors
- Paterson, R. W., Brown, R. L., Benjamin, L., Nortley, R., Wiethoff, S., Bharucha, T., Jayaseelan, D. L., Kumar, G., Raftopoulos, R. E., Zambreanu, L., Vivekanandam, V., Khoo, A., Geraldes, R., Chinthapalli, K., Boyd, E., Tuzlali, H., Price, G., Christofi, G., Morrow, J., McNamara, P., McLoughlin, B., Lim, S. T., Mehta, P. R., Levee, V., Keddie, S., Yong, W., Trip, S. A., Foulkes, A. J. M., Hotton, G., Miller, T. D., Everitt, A. D., Carswell, C., Davies, N. W. S., Yoong, M., Attwell, D., Sreedharan, J., Silber, E., Schott, J. M., Chandratheva, A., Perry, R. J., Simister, R., Checkley, A., Longley, N., Farmer, S. F., Carletti, F., Houlihan, C., Thom, M., Lunn, M. P., Spillane, J., Howard, R., Vincent, A., Werring, D. J., Hoskote, C., Jäger, H. R., Manji, H., & Zandi, M. S.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-07-08
- Volume
- 143
- Issue
- 10
- Pages
- 3104-3120
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W3040794648
- Cited by
- 1,124
- References
- 43
- FWCI
- 91.35
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.